Efavaleukin alfa is an experimental drug that works as an interleukin-2 "mutein Fc fusion protein that preferentially binds the high-affinity IL-2 receptor alpha chain (CD25) to selectively promote Treg expansion".[1] It is developed to treat systemic lupus erythematosus (SLE).[2][3][4]
References
- ^ Sarkar, N.; Hu, X.; Tchao, N.; Furie, R.; Kivitz, A.; Cohen, S.; Gorski, K. (1 June 2023). "Op0140 Regulatory T Cell Defects in Sle and Therapy with a Novel Il-2 Mutein: Phase 1 Clinical Results with Efavaleukin Alfa". Annals of the Rheumatic Diseases. 82 (Suppl 1): 92–93. doi:10.1136/annrheumdis-2023-eular.369. ISSN 0003-4967.
- ^ Cully, Megan (6 August 2021). "T cell-regulating therapies for autoimmune diseases take FDA rejection in stride". Nature Reviews Drug Discovery. 20 (9): 655–657. doi:10.1038/d41573-021-00137-0.
- ^ Garces, Sandra; Karis, Elaine; Merrill, Joan T; Askanase, Anca D; Kalunian, Kenneth; Mo, May; Milmont, Cassandra E (July 2023). "Improving resource utilisation in SLE drug development through innovative trial design". Lupus Science & Medicine. 10 (2): e000890. doi:10.1136/lupus-2022-000890.
- ^ Tchao, N.; Sarkar, N.; Hu, X.; Zhang, R.; Milmont, C.; Jin, Y. Shi; Chow, V.; Kroenke, M.; Gorski, K.; Furie, R.; Kivitz, A.; Cohen, S. (1 June 2022). "Ab0432 Efavaleukin Alfa, a Novel Il-2 Mutein, Selectively Expands Regulatory T Cells in Patients with Sle: Final Results of a Phase 1b Multiple Ascending Dose Study". Annals of the Rheumatic Diseases. 81 (Suppl 1): 1343–1344. doi:10.1136/annrheumdis-2022-eular.2244. ISSN 0003-4967.
This page was last edited on 28 November 2023, at 04:00